TIGIT is a CD8 + effector memory T cell inhibitory molecule that interacts with PVR to inhibit anti-tumor immune responses, and PVRL1/TIGIT inhibitors and anti-PD1 antibodies could be developed to treat HCC52. Here, PDCD1 is linked to neoplasm.